REPL Replimune
- 6.950
- +0.390+5.95%
- 7.080
- +0.130+1.87%
Replimune News
Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)
Positive Outlook for Replimune Group With Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
BMO Capital Keeps Their Buy Rating on Replimune Group (REPL)
Replimune Group (REPL) Receives a Buy From BTIG
BTIG Keeps Their Buy Rating on Replimune Group (REPL)
Balanced Outlook: Replimune's Setbacks and Potential in Clinical Trials Justify Buy Rating
Barclays Maintains Overweight on Replimune Group, Lowers Price Target to $13
Replimune Group Analyst Ratings
JPMorgan Adjusts Replimune Price Target to $38 From $42, Maintains Overweight Rating
HC Wainwright & Co. Maintains Buy on Replimune Group, Lowers Price Target to $48
Replimune Group Analyst Ratings
Promising Clinical Trial Results and Financial Stability Lead to Buy Rating for Replimune Group
Wedbush Reiterates Outperform on Replimune Group, Maintains $52 Price Target
Replimune Group Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK), Replimune Group (REPL) and Precision BioSciences (DTIL)
Promising Skin Cancer Treatment and Future Prospects Bolster Replimune Group's Buy Rating: An Analysis of Jonathan Chang's Recommendation
Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Capricor Therapeutics (CAPR) and Intellia Therapeutics (NTLA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Replimune Group (REPL) and Verve Therapeutics (VERV)
HC Wainwright & Co. Maintains Buy on Replimune Group, Lowers Price Target to $50
Analysis
Price Target
No Data
